Page 57 - GPD-3-4

Gene & Protein in Disease Immune checkpoint blocker and NK cell activation

N Engl J Med. 2020;383(14):1328-1339. activation motif is involved in activating NK cells. Nature.
1998;391(6668):703-707.
doi: 10.1056/NEJMoa1917346
78. Morvan MG, Lanier LL. NK cells and cancer: You can teach doi: 10.1038/35642
innate cells new tricks. Nat Rev Cancer. 2016;16(1):7-19. 89. Duan S, Guo W, Xu Z, et al. Natural killer group 2D receptor
and its ligands in cancer immune escape. Mol Cancer.
doi: 10.1038/nrc.2015.5
2019;18(1):29.
79. Sun JC, Lanier LL. NK cell development, homeostasis and
function: Parallels with CD8⁺ T cells. Nat Rev Immunol. doi: 10.1186/s12943-019-0956-8
2011;11(10):645-657. 90. Zompi S, Hamerman JA, Ogasawara K, et al. NKG2D
doi: 10.1038/nri3044 triggers cytotoxicity in mouse NK cells lacking DAP12 or
Syk family kinases. Nat Immunol. 2003;4(6):565-572.
80. Yu J, Freud AG, Caligiuri MA. Location and cellular
stages of natural killer cell development. Trends Immunol. doi: 10.1038/ni930
2013;34(12):573-582. 91. Bahram S, Bresnahan M, Geraghty DE, Spies T. A second
doi: 10.1016/j.it.2013.07.005 lineage of mammalian major histocompatibility complex
class I genes. Proc Natl Acad Sci U S A. 1994;91(14):6259-6263.
81. Voskoboinik I, Whisstock JC, Trapani JA. Perforin and
granzymes: Function, dysfunction and human pathology. doi: 10.1073/pnas.91.14.6259
Nat Rev Immunol. 2015;15(6):388-400. 92. Zhang J, Basher F, Wu JD. NKG2D ligands in tumor
doi: 10.1038/nri3839 immunity: Two sides of a coin. Front Immunol. 2015;6:97.
82. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. doi: 10.3389/fimmu.2015.00097
Functions of natural killer cells. Nat Immunol. 93. González S, López-Soto A, Suarez-Alvarez B, López-
2008;9(5):503-510. Vázquez A, López-Larrea C. NKG2D ligands: Key targets of
doi: 10.1038/ni1582 the immune response. Trends Immunol. 2008;29(8):397-403.
83. Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence doi: 10.1016/j.it.2008.04.007
analysis of NKG2, a family of related cDNA clones encoding 94. Zhuang L, Fulton RJ, Rettman P, et al. Activity of IL-12/15/18
type II integral membrane proteins on human natural killer primed natural killer cells against hepatocellular carcinoma.
cells. J Exp Med. 1991;173(4):1017-1020. Hepatol Int. 2019;13(1):75-83.
doi: 10.1084/jem.173.4.1017 doi: 10.1007/s12072-018-9909-3
84. Yabe T, McSherry C, Bach FH, et al. A multigene family on 95. Konjević G, Mirjačić Martinović K, Vuletić A, Babović N.
human chromosome 12 encodes natural killer-cell lectins. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK
Immunogenetics. 1993;37(6):455-460. cell receptor expression indicates novel aspects of NK cell
doi: 10.1007/bf00222470 activation in metastatic melanoma patients. Melanoma Res.
2010;20(6):459-467.
85. Diefenbach A, Tomasello E, Lucas M, et al. Selective
associations with signaling proteins determine stimulatory doi: 10.1097/CMR.0b013e32833e3286
versus costimulatory activity of NKG2D. Nat Immunol. 96. Song H, Hur DY, Kim KE, et al. IL-2/IL-18 prevent the
2002;3(12):1142-1149. down-modulation of NKG2D by TGF-beta in NK cells via
doi: 10.1038/ni858 the c-Jun N-terminal kinase (JNK) pathway. Cell Immunol.
2006;242(1):39-45.
86. Wu J, Song Y, Bakker AB, et al. An activating
immunoreceptor complex formed by NKG2D and DAP10. doi: 10.1016/j.cellimm.2006.09.002
Science. 1999;285(5428):730-732.
97. Weiss T, Schneider H, Silginer M, et al. NKG2D-dependent
doi: 10.1126/science.285.5428.730 antitumor effects of chemotherapy and radiotherapy against
glioblastoma. Clin Cancer Res. 2018;24(4):882-895.
87. Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD,
Leibson PJ. NKG2D-mediated signaling requires a DAP10- doi: 10.1158/1078-0432.ccr-17-1766
bound Grb2-Vav1 intermediate and phosphatidylinositol- 98. Okita R, Yukawa T, Nojima Y, et al. MHC class I chain-
3-kinase in human natural killer cells. Nat Immunol. related molecule A and B expression is upregulated by
2006;7(5):524-532.
cisplatin and associated with good prognosis in patients with
doi: 10.1038/ni1325 non-small cell lung cancer. Cancer Immunol Immunother.
2016;65(5):499-509.
88. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH.
Immunoreceptor DAP12 bearing a tyrosine-based doi: 10.1007/s00262-016-1814-9

Volume 3 Issue 4 (2024) 9 doi: 10.36922/gpd.3804